The JMJD7 Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-mediated gene disruption model in the A-549 human lung adenocarcinoma cell line. This product is supplied as a polyclonal knockout cell population, wherein the JMJD7 gene has been targeted for loss-of-function studies. The use of CRISPR/Cas9 technology enables robust ablation of JMJD7 expression, providing a valuable tool for investigating the gene’s role in cellular processes without the clonal variability associated with monoclonal isolates.
A-549 cells are an epithelial cell line originally derived from human lung adenocarcinoma tissue, widely employed as a model system for lung cancer research. These cells exhibit characteristics of type II alveolar epithelial cells and are extensively characterized for studies on cancer biology, drug response, and signal transduction. The A-549 background provides a relevant cellular context for dissecting the functions of JMJD7 in lung adenocarcinoma, a disease where epigenetic dysregulation plays a prominent role.
JMJD7 encodes a protein that is predicted to function as a histone demethylase and protein hydroxylase, bridging epigenetic regulation and post-translational modification. Although its direct molecular partners remain unknown, JMJD7 is implicated in the control of gene expression through histone modification and the hydroxylation of target proteins, potentially affecting translation factor activity. Representative pathway components associated with JMJD7 function include histone modification enzymes and translation factors, suggesting involvement in chromatin remodeling and protein synthesis regulation.
Given its putative enzymatic activities, JMJD7 may contribute to the epigenetic landscape alterations observed in lung adenocarcinoma. Its expression has been noted to be altered in certain cancers, hinting at a possible role in tumorigenesis. Disruption of JMJD7 in A-549 cells allows researchers to interrogate its contributions to cancer cell proliferation, survival, and epigenetic reprogramming, thereby advancing the understanding of lung adenocarcinoma pathogenesis.
This polyclonal knockout model supports diverse experimental applications, including functional characterization of JMJD7 through gene expression profiling by RNA-seq, chromatin binding studies via ChIP-qPCR, and protein-level analyses using Western blotting and RT-qPCR. Phenotypic assays such as proliferation, apoptosis, and flow cytometry can be employed to assess the impact of JMJD7 loss on lung cancer cell behavior. These studies facilitate the identification of epigenetic therapy targets and deepen insights into the molecular mechanisms of lung cancer. For additional technical details, please contact Ascent Research.
